NCT02086175

A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 25 (actual)
• Sponsor: Dana-Farber Cancer Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This research study is evaluating a drug combination called Imprime PGG and Rituximab as a possible treatment for relapsed/refractory indolent B cell non-Hodgkin lymphomas (NHL).

Detailed description

After the screening procedures confirms eligibility: Study Drugs: The participant will receive both Imprime PGG and rituximab weekly, for four weeks. Clinical Exams: At the participant's weekly visit there will be have a physical exam and general health and specific questions about any problems they might be having and any medications the participant may be taking. Scans (or Imaging tests):The Investigator will measure the participant's tumor 10 weeks after Week 4 of treatment by CT scan. Additional scans will be performed at 6 months and 12 months following the end of treatment.

Conditions

• Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas

Interventions

Type	Name	Description
DRUG	Imprime PGG
DRUG	Rituximab

Timeline

• Start date: 2014-12-01
• Primary completion: 2019-07-11
• Completion: 2021-02-01
• First posted: 2014-03-13
• Last updated: 2026-04-06
• Results posted: 2021-01-07

Locations

1 site across 1 country: United States